CETP and cerebrovascular disorder: Some clinical trials also have shown that some drugs that increase HDL-C levels, such as cholesteryl ester transfer protein (CETP) inhibitors and niacin, cannot decrease the risk of cardiovascular and cerebrovascular diseases [11–13].